Why the most advanced drug discovery process is still an expensive, inefficient gamble
In short: Modern medicine relies on a complex, capital-intensive hunt for new treatments. Despite massive investments and cutting-edge technology, the path from a laboratory concept to a pharmacy shelf remains notoriously difficult. Discover how scientists navigate the tension between high-throughput screening, natural product chemistry, and the quest for the next breakthrough.
Drug discovery is the foundational process of identifying candidate medications, a field that has evolved from serendipitous observations to highly engineered scientific workflows. Historically, medicine relied on traditional remedies or accidental discoveries, such as the 1928 identification of penicillin. Today, the industry primarily utilizes reverse pharmacology, where researchers identify a specific biological target—often a protein like a kinase or G-protein-coupled receptor—and then screen massive chemical libraries to find molecules that can modify its function.
This modern approach is capital-intensive, with research and development costs for a single new molecular entity estimated at about US$1.8 billion in 2010. The process typically begins with high-throughput screening, where thousands of compounds are tested against a target. However, this method is increasingly criticized for its inefficiency. Many synthetic libraries cover a limited chemical space compared to natural products, which remain a vital source of inspiration. Between 1981 and 2006, 63% of new small molecule entities were derived from or inspired by natural sources, such as plant metabolites, animal venoms, or microbial defenses.
To improve success rates, researchers are shifting toward more nuanced strategies. These include fragment-based lead discovery, which uses smaller libraries to explore chemical space more effectively, and the use of human organoids—3D tissues derived from stem cells—to better model disease. Additionally, computational tools like quantum computing and virtual screening are helping to refine lead compounds by predicting how they might interact with biological targets. Despite these innovations, the transition from a laboratory hit to a clinical candidate remains a rigorous gauntlet, requiring optimization for potency, metabolic stability, and safety before a drug can even enter the lengthy phase of clinical trials.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Drug discovery
- Also: Drug discovery - Latest research and news | Nature
- Also: Stem cell reports — Human organoids: Fit for drug discovery? · CC BY
To cite this card, link to https://intellectplus.co.uk/app/health-drug-discovery.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Drugs and medication · More in Health · Latest · A–Z · All topics
